ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Diabetes and endocrinology · Diabetes Care · 2026-08-01

Secondary analysis of the TriMaster crossover trial (309 adults with type 2 diabetes given sitagliptin, canagliflozin and pioglitazone): a routine-features prediction model beat cluster-based allocation for HbA1c reduction (0.27% vs 0.16%); DDRTree showed no association.

Secondary analysisn = 309
Güdemann et al. To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial
Diabetes and endocrinology · Diabetologia · 2026-03-12

Post hoc analysis of CREDENCE (2573 participants with type 2 diabetes and CKD): canagliflozin vs placebo reduced heart failure/CV death with low-normal sodium intake (adjHR 0.48) but not high intake (adjHR 1.05); renal benefit in both groups; no effect on all-cause death.

Secondary analysisn = 2,573
Chiriacò et al. Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial
Diabetes and endocrinology · Diabetologia · 2026-02-24

Open-label RCT in 45 adults with type 2 diabetes at high cardiovascular risk: 26 weeks of canagliflozin vs sitagliptin reduced CMR-measured extracellular volume, a marker of myocardial fibrosis (adjusted mean difference -3.67%), with similar HbA1c falls.

RCTn = 45
Yan et al. Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.